The information in these press releases is accurate only as of the date of the particular press release. Theravance does not update press releases once they have been made public. Press releases may contain forward-looking statements and future events or actual results could differ materially from those projected in the forward-looking statements.
 |
GlaxoSmithKline Completes Transaction to Increase Its Ownership in Theravance
May 16, 2012
|
13.9 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, Calif., May 16, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc ("GSK") (LSE:GSK) and Theravance, Inc. ("Theravance") (Nasdaq:THRX) announced today that following approval by Theravance, Inc.'s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-...
|
|
Theravance to Webcast 2012 Annual Meeting of Stockholders on May 15, 2012
May 8, 2012
|
10.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it will webcast its 2012 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Tuesday, May 15, 2012.
An accompanying listen-only...
|
|
Theravance Reports First Quarter 2012 Financial Results
Apr 26, 2012
|
60.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 26, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) reported today its financial results for the quarter ended March 31, 2012. Revenue for the first quarter of 2012 was $127.1 million. Net income for the first quarter of 2012 was $84.6 million or $0.93 per diluted share. Cash, cash equivalents, and marketa...
|
|
Theravance to Present at Investor Conferences in May 2012
Apr 24, 2012
|
11.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 24, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that Theravance management is scheduled to present at the following investor conferences in May 2012:
Deutsche Bank 37th Health Care Conference
InterContinental, Boston, MA
Tuesday, May 8, 2012
10:00 a.m. EDT
...
|
|
Theravance to Report First Quarter 2012 Financial Results on April 26, 2012
Apr 12, 2012
|
9.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 12, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it will release financial results for the period ended March 31, 2012 after market close on Thursday, April 26, 2012.
An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call...
|
|
GlaxoSmithKline to Increase Its Ownership in Theravance
Apr 2, 2012
|
16.1 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, Calif., April 2, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) announced today that they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will acquire, 10,000,000 shares of Theravance common stock at a price of $21.2887 per share, for a t...
|
|
Theravance to Present at the 11th Annual Needham Healthcare Conference
Mar 27, 2012
|
17.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 27, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that Mathai Mammen, M.D., Ph.D., Theravance's Senior Vice President, Research and Early Clinical Development, is scheduled to present at the 11th Annual Needham Healthcare Conference on Wednesday, April 4, 2012, at 3:20 p.m. EDT. The confe...
|
|
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational Programme and Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD
Mar 23, 2012
|
124.4 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, Calif., March 23, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced that the registrational programme for Relovair™ is now complete. In addition, results from two studies for the once-daily investigational medicine Relovair™ (fluticasone furoate "FF"/vilante...
|
|
Theravance to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 22, 2012
|
10.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Cowen and Company 32nd Health Care Conference on Tuesday, March 6, 2012, at 8:40 a.m. EST. The conference will be held from March 5-7, 2012 at the ...
|
| |
Theravance Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 9, 2012
|
77.7 KB |
|
| |
Theravance to Present at Investor Conferences in February 2012
Feb 1, 2012
|
26.6 KB |
|
| |
Theravance to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012
Jan 26, 2012
|
20.9 KB |
|
| |
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma
Jan 9, 2012
|
131.7 KB |
|
| |
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
Jan 6, 2012
|
81.6 KB |
|
| |
Theravance to Present at the 30th Annual J.P. Morgan Healthcare Conference
Dec 28, 2011
|
25.2 KB |
|
| |
Theravance Announces Initiation of Phase 2 Study with Its MARIN Compound, TD-9855, for the Treatment of ADHD
Dec 12, 2011
|
86.7 KB |
|
| |
Theravance Announces Positive Results from a Phase 2a Study of its LAMA Candidate, TD-4208, for the Treatment of COPD
Nov 14, 2011
|
132.6 KB |
|
| |
Theravance to Present at Investor Conferences in November 2011
Nov 1, 2011
|
26.6 KB |
|
| |
Theravance Reports Third Quarter 2011 Financial Results
Oct 27, 2011
|
81.1 KB |
|
| |
Theravance Announces Presentation of GSK Phase 2 Data for LAMA (GSK573719) at CHEST 2011
Oct 19, 2011
|
18.7 KB |
|
|
|
